Erythropoietin (EPO) is used in many clinical settings for anaemic patients. Increasing incidence of chronic diseases such as end-stage renal diseases, cancer, and HIV is expected to accelerate demand for EPO as these diseases may cause anemia. A second-generation erythropoietin analogue, Darbepoetin alpha, was created aiming longer elimination half-life in vivo that translated into less frequent dosing, usually once weekly or once every 2 week. EPO and Darbepoetin drugs market size was valued at USD 7.4 billion in 2016 and is expected to witness CAGR of 11.5% during 2018-2025 as a result of global rising incidence of anemia. 1 Present technology provides a booster kit to enhance the production of EPO and Darbepoetin proteins.